Phaseline

Targets › GZMB

GZMB (Granzyme B): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 2 Phase 1; Oncology; next expected readout Dec 2026.

Abundant protease in the cytosolic granules of cytotoxic T-cells and NK-cells which activates caspase-independent pyroptosis when delivered into the target cell through the immunological synapse. It cleaves after Asp. (UniProt, P10144)

Open in Phaseline: the race on GZMB, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Rahul Aggarwal64Cu-GRIP B
Copper-64 labeled granzyme B targeting radiotracer for PET imaging
GZMBPhase 1Prostate CancerDec 2026
Michael Randall64Cu-GRIP B
64-copper labeled granzyme B-targeting peptide for PET imaging
GZMBPhase 1Non Hodgkin LymphomaJan 2027

Conditions

Prostate Cancer (1) Non Hodgkin Lymphoma (1)

Modalities

small molecule (1), protein or peptide (1)

Companies

Rahul Aggarwal (1) Michael Randall (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.